Marco Haselager

Research output

Research output per year 2018 2020 2023 2023

• 5 Article
• 2 Review article
• 1 Phd-Thesis - Research and graduation internal

Research output per year

Research output per year

Search results

• 2023

  Ibrutinib sensitizes CLL cells to venetoclax by interrupting TLR9-induced CD40 upregulation and protein translation

  Kielbassa, K., Haselager, M. V., Bax, D. J. C., van Driel, B. F., Dubois, J., Levin, M-D., Kersting, S., Svanberg, R., Niemann, C. U., Kater, A. P. & Eldering, E., Jun 2023, In: Leukemia. 37, 6, p. 1268-1276 9 p.

  Research output: Contribution to journal › Article › Academic › peer-review

  Open Access
  5 Citations (Scopus)

• In Vitro 3D Spheroid Culture System Displays Sustained T Cell-dependent CLL Proliferation and Survival

  Haselager, M. V., van Driel, B. F., Perelaer, E., de Rooij, D., Lashgari, D., Loos, R., Kater, A. P., Moerland, P. D. & Eldering, E., 23 Sept 2023, In: HemaSphere. 7, 9, p. E938

  Research output: Contribution to journal › Article › Academic › peer-review

  Open Access
  2 Citations (Scopus)

• JAK–STAT signalling shapes the NF-κB response in CLL towards venetoclax sensitivity or resistance via Bcl-XL

  Haselager, M. V., Thijssen, R., Bax, D., Both, D., de Boer, F., Mackay, S., Dubois, J., Mellink, C., Kater, A. P. & Eldering, E., Jun 2023, In: Molecular Oncology. 17, 6, p. 1112-1128 17 p.

  Research output: Contribution to journal › Article › Academic › peer-review

  Open Access
  7 Citations (Scopus)
• 2022

  The Therapeutic Potential of Targeting NIK in B Cell Malignancies

  Haselager, M. V. & Eldering, E., 12 Jul 2022, In: Frontiers in immunology. 13, 930986.

  Research output: Contribution to journal › Review article › Academic › peer-review

  Open Access
  5 Citations (Scopus)
• 2021

  From signaling to survival: Dissecting drug resistance and proliferation in CLL

  Haselager, M. V., 2021, 226 p.

  Research output: PhD Thesis › Phd-Thesis - Research and graduation internal

  Open Access
• 2020

  Changes in Bcl-2 members after ibrutinib or venetoclax uncover functional hierarchy in determining resistance to venetoclax in CLL

  Haselager, M. V., Kielbassa, K., ter Burg, J., Bax, D. J. C., Fernandes, S. M., Borst, J., Tam, C., Forconi, F., Chiodin, G., Brown, J. R., Dubois, J., Kater, A. P. & Eldering, E., 17 Dec 2020, In: Blood. 136, 25, p. 2918-2926 9 p.

  Research output: Contribution to journal › Article › Academic › peer-review

  Open Access
  65 Citations (Scopus)

• Proliferative Signals in Chronic Lymphocytic Leukemia; What Are We Missing?

  Haselager, M. V., Kater, A. P. & Eldering, E., 8 Oct 2020, In: Frontiers in Oncology. 10, 592205.

  Research output: Contribution to journal › Review article › Academic › peer-review

  Open Access
  28 Citations (Scopus)
• 2018

  Stroma-induced phenotypic plasticity offers phenotype-specific targeting to improve melanoma treatment

  Seip, K., Jørgensen, K., Haselager, M. V., Albrecht, M., Haugen, M. H., Egeland, E. V., Lucarelli, P., Engebraaten, O., Sauter, T., Mælandsmo, G. M. & Prasmickaite, L., 28 Dec 2018, In: Cancer Letters. 439, p. 1-13 13 p.

  Research output: Contribution to journal › Article › Academic › peer-review